Reviews:
Targeting WNT5B and WNT10B in osteosarcoma
PDF | Full Text | How to cite | Press Release
Metrics: PDF 523 views | Full Text 2029 views | ?
Abstract
Gustavo A. Miranda-Carboni1,2 and Susan A. Krum2,3
1 Department of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA
2 Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN 38163, USA
3 Department of Orthopaedic Surgery and Biomedical Engineering, University of Tennessee Health Science Center, Memphis, TN 38163, USA
Correspondence to:
Susan A. Krum, | email: | [email protected] |
Keywords: WNT5B; WNT10B; WNT signaling; osteosarcoma
Received: June 24, 2024 Accepted: July 15, 2024 Published: August 02, 2024
ABSTRACT
WNT signaling regulates osteosarcoma proliferation. However, there is controversy in the field of osteosarcoma as to whether WNT signaling is pro- or anti-tumorigenic. WNT-targeting therapeutics, both activators and inhibitors, are compared. WNT5B, a β-catenin-independent ligand, and WNT10B, a β-catenin-dependent WNT ligand, are each expressed in osteosarcomas, but they are not expressed in the same tumors. Furthermore, WNT10B and WNT5B regulate different histological subtypes of osteosarcomas. Using WNT signaling modulators as therapeutics may depend on the WNT ligand and/or the activated signaling pathway.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28617